Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies

As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems...

Full description

Bibliographic Details
Main Authors: Arif Hussain, Anwarul Hasan, Mohammad Mahdi Nejadi Babadaei, Samir Haj Bloukh, Muhammad E.H. Chowdhury, Majid Sharifi, Setareh Haghighat, Mojtaba Falahati
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Corona virus
spike protein
receptor binding domain
antibodies
epitope-specific vaccines (ESV)
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220307526

Internet

http://www.sciencedirect.com/science/article/pii/S0753332220307526

Similar Items